MINNEAPOLIS, April 26, 2011 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the manufacturer and marketer of minimally invasive Cooled ThermoTherapyTM (CTT), the durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today announced publication of long-term data in the May issue of The Journal of Urology. The study was conducted at leading urology centers in the US including: The Mayo Clinic, Johns Hopkins University Hospital, University of Texas Southwestern Medical Center, Duke University Medical Center and Virginia Urology Center. The study tracked 96% of patients through the duration of the study. The study is available through the following link: http://www.jurology.com/article/S0022-5347%2810%2905396-6
